How often does post-treatment SPECT/CT impact patient management during Radiopharmaceutical Prostate Cancer Treatment

Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy, published in Journal of Nuclear Medicine, the study revealed that nearly 50% of patients experienced a change in management based on posttreatment SPECT/CT.

Measuring Where Radiopharmaceuticals Concentrate with Digital Autoradiography

3D small-scale dosimetry and tumor control of 225Ac radiopharmaceuticals for prostate cancer, published in Scientific Reports, explores methods of measuring the spatial dose distribution of radiopharmaceuticals in organs and tumors, to inform treatment dose prescription and reduce off-target...